EUCTR2017-001567-20-FRActive, not recruitingPhase 1
Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study - ADRIFT
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)0 sites90 target enrollmentStarted: May 2, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 3
To Compare Longterm Single versus Dual Antiplatelet Therapy In Ischemic Stroke due to atherosclerotic narrowing of blood vessel in the brain.CTRI/2022/01/039445Dr Rohit Bhatia
Active, not recruiting
Phase 1
Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgeryEUCTR2017-001754-33-ITIVERSITÀ CAMPUS BIO-MEDICO DI ROMA800
Completed
Not Applicable
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
Completed
Not Applicable
Impact of 1-month Dual Antiplatelet Therapy After Treatment with Drug-Coated Balloon for Femoropopliteal Artery DiseaseArteriosclerosis obliteransJPRN-UMIN000034867Hyogo College of Medicine151
Active, not recruiting
Not Applicable
Clinical trial to evaluate treatment after percutaneous aortic valve implantatioEUCTR2011-005784-24-ESAndres Iñiguez Romo120